Baillie Gifford Amends AbCellera Biologics Stake
Ticker: ABCL · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1703057
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investing
TL;DR
**Baillie Gifford just updated their AbCellera Biologics stake, watch for potential price movement.**
AI Summary
Baillie Gifford & Co., a prominent investment management firm, filed an amended SC 13G/A on January 29, 2024, indicating a change in their ownership of AbCellera Biologics Inc. common shares as of December 29, 2023. This filing updates their previous disclosure, signaling a potential adjustment in their investment strategy or a rebalancing of their portfolio regarding AbCellera. For investors, this matters because large institutional ownership changes can influence stock price and reflect a major investor's confidence (or lack thereof) in the company's future prospects.
Why It Matters
This filing shows a significant institutional investor, Baillie Gifford & Co., has updated its position in AbCellera Biologics, which can signal a shift in their outlook on the company's value or future performance.
Risk Assessment
Risk Level: medium — Changes in institutional ownership can introduce volatility and uncertainty, as other investors may react to the actions of large funds.
Analyst Insight
An investor should monitor subsequent filings from Baillie Gifford & Co. or other major institutions to understand the magnitude and direction of their ownership changes in AbCellera Biologics Inc., as this could signal broader institutional sentiment.
Key Players & Entities
- Baillie Gifford & Co. (company) — the reporting person and investment management firm
- AbCellera Biologics Inc. (company) — the subject company whose securities are being reported
- December 29, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G/A amendment
- 00288U106 (number) — the CUSIP number for AbCellera Biologics Inc. Common Shares
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, indicating a change in beneficial ownership by a passive institutional investor.
Who is the reporting person in this filing?
The reporting person is Baillie Gifford & Co., an investment management firm based in Edinburgh, Scotland.
What is the subject company whose securities are being reported?
The subject company is AbCellera Biologics Inc., a pharmaceutical preparations company based in Vancouver, Canada.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 29, 2023.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Shares of AbCellera Biologics Inc. is 00288U106.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding AbCellera Biologics Inc. (ABCL).